key: cord-0958244-2sihv0z0
authors: Bartsch, Y. C.; Cizmeci, D.; Kang, J.; Gao, H.; Shi, W.; Chandrashekar, A.; Collier, A.-r. Y.; Chen, B.; Barouch, D. H.; Alter, G.
title: BA.2 evasion of vaccine induced binding and functional non-neutralizing antibodies
date: 2022-02-28
journal: nan
DOI: 10.1101/2022.02.25.22271511
sha: d96feb66a7db604ae3689548b59a76bbb606d283
doc_id: 958244
cord_uid: 2sihv0z0

The number of mutations in the omicron (B1.1.529) BA.1 variant of concern (VOC) led to an unprecedented evasion of vaccine induced immunity. However, despite the remarkable rise in global infections, severe disease and death did not increase proportionally, linked to persistent recognition of BA.1 by T cells and non-neutralizing opsonophagocytic antibodies. Yet, the emergence of a new sublineage, BA.2, that is more transmissible compared to BA.1, despite relatively preserved neutralizing antibody responses, has raised the possibility that BA.2 may evade other vaccine induced responses that may be key to protection against infection and disease. Here we comprehensively profiled the BNT162b2 vaccine induced response to several VOCs including the omicron BA.1 and BA.2, after the primary vaccine series, 8 months following vaccination, and after a boost. While vaccine induced immune responses were compromised against both Omicron sublineages, vaccine induced antibody isotype titers, Fc{gamma}R3a- and Fc{gamma}R3b-receptor binding levels, and non-neutralizing opsonophagocytic functions were significantly attenuated to the omicron BA.2 Spike compared to the BA.1 lineage. Conversely, Fc{gamma}R2a and Fc{gamma}R2b binding was elevated to BA.2 potentially contributing to persistent protection against severity of disease. These data point to an attenuation of particular non-neutralizing antibody properties that may be key to protection against transmission, but the maintenance of others that may continue to confer protection against disease.

The rapid and perpetual evolution of SARS-CoV-2 continues to raise concerns related to the potential evolution of more pathogenic variants able to evade natural or vaccine induced immune responses. With each wave of variants of concern (VOCs), SARS-CoV-2 has acquired mutations that have increased infectivity, either via stabilization of the spike, enhanced binding to the angiotensin converting enzyme-2 (ACE-2), or via alterations in the viral fusion machinery (1-3). Evasion from neutralizing antibodies has progressed in parallel to this evolution, due to the natural accumulation of mutations near or around sites involved in infection and fusion (4, 5) . The most recent variant of concern, omicron, has exhibited the greatest evolutionary leap, acquiring 36 mutations, deletions, or insertions in the Spike antigen, associated with significant evasion of vaccine induced neutralizing antibodies and increased infectivity. However, despite this remarkable increase in transmissibility, the omicron BA.1 variant has exhibited overall lower pathogenicity and disease (5) (6) (7) (8) ).

Yet, a new omicron sublineage has recently emerged, the BA.2 lineage. While BA.2 Spike lacks 16 alterations characteristic to BA1 it has acquired 11 unique additional amino acid changes that are speculated to have increased BA.2 infectivity by 30% over BA.1 (9) . The BA.2 lineage has now taken over the epidemic across Southeast Asia, Africa, Denmark, and is on the rise across Europe and the Americas (10) . Like the parental BA.1, BA.2 evades natural or waning vaccine induced neutralizing antibodies equally but can be neutralized with boosting (11, 12) .

While neutralizing antibodies show minimally changed reactivity to BA.2, we speculated that other immune mechanisms may lose potency against BA.2, enabling this lineage to spread more efficiently. In addition to neutralization, antibodies contribute to prevention of infection via their ability to leverage the innate immune response, including the recruitment of opsonophagocytic, via the recruitment of innate cellular function via Fc-receptors. Given the accumulating data pointing to a role for Fc-effector function in protection against severe COVID-19, monoclonal therapeutic efficacy, as well as vaccine mediated protection (13) (14) (15) (16) , here we aimed to define whether BA.2 evades these additional functions of the BNT16b2 vaccine induced humoral immune response at peak immunogenicity after the primary series, after 8 months, as well as after a boost. We observed significant differences in vaccine induced immunity to BA.1 and BA.2, marked by significantly lower antibody binding titers, selective loss of BA.2 FcR3a and FcR3b binding antibodies, as well as reduced neutrophil opsonophagocytic function to BA.2. Thus, despite the near identical neutralizing antibody responses to BA.2, vaccine induced Fc-effector functions are selectively compromised to BA.2, potentially marking a weakened mucosal opsonophagocytic response to this virus that may be key to attenuating mucosal transmission.

Despite nearly identical vaccine induced neutralizing antibody responses to the BA.1 and BA.2, the BA.2 sublineage exhibits a 30% increase in infectiousness and a potential increase in disease severity (9) , calling into question whether this mutant may evade vaccine induced immunity in a manner that is distinct from the original omicron BA.1 variant. Thus, to begin we probed the ability of Pfizer BNT162b2 vaccine induced antibodies to bind across variants of concern (VOCs) including the wildtype/wuhan, Alpha, Beta, Delta, and Omicron BA.1 and BA.2 variants at peak immunogenicity (2 weeks after the primary first and second vaccine), after 8 months, and 2 weeks following a BNT162b2 boost (Figure 1) . Binding IgM, IgA, and IgG responses were probed. Robust IgM binding titers were observed across most VOCs after the primary series, albeit response to BA.1 were lower and lowest to BA.2. IgM responses were rapidly lost over time and were not boosted against the beta, delta, or omicron Spikes ( Figure 1A) . A similar profile was observed in the IgA response ( Figure 1B) (Figure 1C) , IgG levels waned markedly for all VOCs, but most considerably to omicron binding IgG levels. All VOC IgG levels were boosted after the third dose of BNT162b2, although IgG to BA.2 did not boost proportionately. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ; https://doi.org/10.1101/2022.02.25.22271511 doi: medRxiv preprint

Early Phase 3 vaccine trial immune correlates analyses, at a time when DG14G/Wuhan and the alpha variant dominated the global pandemic, pointed to the importance of neutralizing antibodies in protection against COVID-19 (17) . However, the emergence of the beta, delta and now omicron variants of concern, that significantly evade neutralizing antibody responses but do not cause more disease among vaccinated populations (5) (6) (7) (8) , has raised the possibility that alternative vaccine induced immune responses may be key to protection. Both vaccine induced T cell and non-neutralizing antibody responses have shown enhanced resilience to VOCs and have been proposed to contribute to attenuated disease against these evolving neutralizing antibody-escaping variants. However, the emergence of the omicron BA.2 sublineage has begun to challenge this hypothesis. Specifically, BA.2 exhibits enhanced transmissibility compared to the BA.1 lineage, despite only 1.5-fold reduced neutralizing antibody activity to BA.2 (12) . Thus, reduced neutralizing antibody cannot account for enhanced transmissibility of this new sublineage of omicron. Given our increasing appreciation for a role for nonneutralizing Fc-effector antibody responses in protection against natural severe disease (18, 19) , in monoclonal therapeutic activity (13) (14) (15) (16) , and in vaccine mediated protection (20) , here we profiled the Pfizer BNT162b2 functional humoral immune response across VOCs including BA.1 and BA.2. As expected, vaccine induced non-neutralizing antibody responses were lower to omicron variants but were most profoundly diminished against the BA.2 Spike antigen.

However, selective Fc-receptor binding deficits were noted, marked by maintained/superior FcR2a/b binding, but reduced FcR3a/3b binding to BA.2 compared to BA.1. Linked to reduced neutrophil opsonophagocytic activity, these data point to a selective loss of IgA/neutrophil functional mucosal immunity, that may be key to protection against transmission, but maintenance of FcR2a/b that may continue to confer protection against disease. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ; https://doi.org/10.1101/2022.02.25.22271511 doi: medRxiv preprint collaborative IgA/IgG opsonophagocytosis may diminish the initial barrier of protection against BA.2, despite relatively preserved neutralization, pointing to opsonophagocytosis, coupled to neutralization, as potential critical correlate of immunity against transmission.

While this study did not explore functional humoral immunity to BA. 

Antigen specific antibody subclass, isotypes, and FcγR binding was analyzed in technical replicates by Luminex technology. Antigens were coupled to Luminex beads (Luminex Corp, TX, USA) by carbodiimide-NHS ester-chemistry with an individual region per antigen. Coupled beads were incubated with diluted plasma sample (1:100 for IgG3, IgM and IgA1, 1:500 for IgG1, FcαR is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ; https://doi.org/10.1101/2022.02.25.22271511 doi: medRxiv preprint a secondary probe at a 1:1000 dilution. After 1 h incubation, excessive secondary reagent was washed away and the relative antibody concentration per antigen determined on an IQue analyzer (IntelliCyt).

Phagocytosis score of primary human neutrophils was determined as described before (23) .

Antigens were biotinylated with NHS-Sulfo-LC-LC kit according to the manufacturer's instruction (Thermo Fisher). Excessive biotin was removed by size exclusion chromatography using Zeba-Spin desalting columns (7kDa cutoff, Thermo Fisher). Biotinylated antigens were coupled to fluorescent neutravidin beads (Thermo Fisher) and incubated with 1:10 diluted plasma. Primary cells were derived from Ammonium-Chloride-Potassium (ACK) buffer lysed whole blood from healthy donors and incubated with immune complexes for 1h at 37°C. Neutrophils were stained for surface CD66b (Biolegend, CA, USA; clone: G10F5) expression, fixed with 4% paraformaldehyde and analyzed an IQue analyzer (IntelliCyt).

A multivariate classification model was built to discriminate humoral profiles between BA.1 and BA.2 specific antibodies. Prior to analysis, all data were normalized using z-scoring. Feature selection was performed using least absolute shrinkage and selection operator (LASSO).

Classification and visualization were performed using partial least square discriminant analysis (PLS-DA). Selected features were ordered according to their Variable Importance in Projection (VIP) score and the first two latent variables (LVs) of the PLS-DA model were used to visualize the samples. These analyses were performed using R package "ropls" version 1.20.0 (29) and "glmnet" version 4.0.2 (30) and the systemseRology R package (v.1.1) (https://github.com/LoosC/systemsseRology).

If not stated otherwise, we assumed non-normal distributions and plots were generated and statistical differences between two groups were calculated in Graph Pad Prism V.9. A paired . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022 2) variants of concern, and Omicron (B.1.1.529) BA.1 and BA.2 subvariants Spike were measured by Luminex. The average value of technical replicates is shown. The data was corrected for background and negative values were set to 100 for graphing purposes. A two-sided paired Wilcoxon test with a Benjamini-Hochberg post-test correcting for multiple comparisons was used to test for statistical differences between BA1 and BA2 titers, respectively. P-values are shown above each dataset.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Individuals received a three-dose regimen of the BNT162b2 vaccine. Samples were taken approx. 4 weeks after the second dose (post 2nd, n=18), before the third dose approx. 8 months after the second dose (pre 3rd, n=14) and approx. 4 weeks after the third dose (post 3rd, n=22). Binding to FcγR2a (A), FcγR2b (B), FcγR3a (C) and FcγR3b (D) of D614G (WT), Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) variants of concern, and Omicron (B.1.1.529) BA.1 and BA.2 subvariants Spike specific antibodies were measured by Luminex. The average value of technical replicates is shown. The data was corrected for background and negative values were set to 100 for graphing purposes. A two-sided paired Wilcoxon test with a Benjamini-Hochberg post-test correcting for multiple comparisons was used to test for statistical differences between BA1 and BA2 titers, respectively. P-values are shown above each dataset.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 28, 2022. ; Figure 3 . Fc functionality of BNT162b2 induced antibodies is superior to BA.1 compared to BA.2 antigen. Antibody-dependent Neutrophil Phagocytosis (ADNP) of D614G, Omicron (B1.1.529) BA.1 or BA.2 specific antibodies was analyzed in BNT162b2 recipients at approx. 4 weeks after the second dose (post 2nd, n=18), before the third dose approx. 8 month after the second dose (pre 3rd, n=14) and approx. 4 weeks after the third dose (post 3rd, n=22). The average value of two donors is shown. The data was corrected for background and negative values were set to 1 for graphing purposes. A two-sided paired Wilcoxon test with a Benjamini-Hochberg post-test correcting for multiple comparisons was used to test for statistical differences between BA1 and BA2 titers, respectively. P-values are shown above each dataset. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 28, 2022. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 28, 2022. ; https://doi.org/10.1101/2022.02.25.22271511 doi: medRxiv preprint

Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta

SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution

The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. medRxiv

SARS-CoV-2 variants, spike mutations and immune escape

Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. bioRxiv

The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. bioRxiv

Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. medRxiv

SARS-CoV-2 T cell responses are expected to remain robust against Omicron. bioRxiv

Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions

Alter, Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms. medRxiv

The human immunoglobulin A Fc receptor FcalphaRI: a multifaceted regulator of mucosal immunity

A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis

Omicron (BA.1) and Sub-Variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative Sequence and Structural-based Computational Assessment

Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines

Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

Analysis of the Human Adult Urinary Metabolome Variations with Age, Body Mass Index, and Gender by Implementing a Comprehensive Workflow for Univariate and OPLS Statistical Analyses

Regularization Paths for Generalized Linear Models via Coordinate Descent

We thank Nancy Zimmerman, Mark and Lisa Schwartz, an anonymous donor (financial support), Terry and Susan Ragon, and the SAMANA Kay MGH Research Scholars award for their support.We acknowledge support from the Ragon Institute of MGH, MIT, and Harvard, the Massachusetts Consortium on Pathogen Readiness (MassCPR) and the Musk foundation. All data associated with

Wilcoxon test with a Benjamini-Hochberg post-test correcting for multiple comparisons was used to test for statistical differences between BA1 and BA2 features at the different timepoints.